Extended Data Fig. 6: Low-dose DXR treatment reduces leukemia-initiating activity only in human leukemia exhibiting chemoresistant pS552-β-cat+ LSCs.
From: Overcoming Wnt–β-catenin dependent anticancer therapy resistance in leukaemia stem cells
From: Overcoming Wnt–β-catenin dependent anticancer therapy resistance in leukaemia stem cells